Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 281 to 290 of 333 total matches.

Two New Drugs for Colon Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004  (Issue 1184)
to human EGFR and blocks activation of receptor-associated kinases, which leads to inhibition of cell ...
Cetuximab (Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab (Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved by the FDA for treatment of patients with metastatic colorectal cancer. Cetuximab is approved for treatment of patients with EGFR-expressing tumors, either in combination regimens with irinotecan (Camptosar)when the cancer has progressed on irinotecan-based therapy, or as monotherapy for those who cannot tolerate irinotecan. Bevacizumab is approved...
Med Lett Drugs Ther. 2004 Jun 7;46(1184):46-8 |  Show IntroductionHide Introduction

Ziconotide (Prialt) for Chronic Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 05, 2005  (Issue 1223)
in combination. 2 Mechanism of action Binds to N-type voltage-sensitive calcium channels; blocks ...
The FDA has approved ziconotide (Prialt - Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic neuronal N-type calcium channel blocker. It is intended for use with a programmable implanted microinfusion device, but an external microinfusion device can be used temporarily.
Med Lett Drugs Ther. 2005 Dec 5;47(1223):103-4 |  Show IntroductionHide Introduction

Proton Pump Inhibitors for GERD in Children

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007  (Issue 1255)
of the day (to block acid pumps synthesized during an overnight fast). 7. For patients with swallowing ...
A recent advertisement for the proton pump inhibitor (PPI) lansoprazole (Prevacid - TAP) suggests that children who cough at night, complain of abdominal pain, refuse to eat, or have a bad taste in their mouths may all have gastroesophageal reflux disease (GERD). A Bunny's Tummy Trouble, a children's book about GERD published by TAP, is now available as a patient handout in pediatricians' waiting rooms. The use of acid-suppressive drugs in infants and children has increased markedly in recent years and many of these drugs are now available in child-friendly formulations. A table in the article...
Med Lett Drugs Ther. 2007 Feb 26;49(1255):17-8 |  Show IntroductionHide Introduction

Paliperidone (Invega) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007  (Issue 1256)
), which block D 2 -dopamine receptors, are effective against psychotic symptoms. SGAs have effects ...
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.
Med Lett Drugs Ther. 2007 Mar 12;49(1256):21-3 |  Show IntroductionHide Introduction

Natalizumab (Tysabri) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • May 05, 2008  (Issue 1285)
endothelium. Natalizumab blocks this process and inhibits the inflammatory cascade. Natalizumab (Tysabri ...
Natalizumab (Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML). It is now available for treatment of both MS and CD through a restricted distribution program.
Med Lett Drugs Ther. 2008 May 5;50(1285):34-6 |  Show IntroductionHide Introduction

Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 22, 2008  (Issue 1295)
q10 min block, cardiogenic shock or or 2 mg/min (300 mg severe bradycardia max) Nitroglycerin ...
Clevidipine (Cleviprex - The Medicines Company), a dihydropyridine calcium channel blocker (CCB), has been approved by the FDA for intravenous (IV) use in lowering high blood pressure. It is the second IV CCB to be marketed in the US; nicardipine has been available in an IV formulation (Cardene IV) for more than 10 years. Like IV nicardipine, clevidipine will probably be used mainly for urgent treatment of hypertension in intensive care units, operating rooms and emergency departments.
Med Lett Drugs Ther. 2008 Sep 22;50(1295):73-5 |  Show IntroductionHide Introduction

Iloperidone (Fanapt) - Another Second-Generation Antipsychotic

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2010  (Issue 1332)
. Pharmacology DRUGS FOR SCHIZOPHRENIA — First-generation antipsychotic agents block dopamine D 2 receptors ...
The FDA has approved the marketing of iloperidone (Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone (Risperdal, and others).
Med Lett Drugs Ther. 2010 Feb 22;52(1332):13-4 |  Show IntroductionHide Introduction

Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer

   
The Medical Letter on Drugs and Therapeutics • May 03, 2010  (Issue 1337)
rejection. Mechanism of action Inhibition of mTOR kinase blocks intracellular signaling pathways related ...
Everolimus (Afinitor – Novartis) and pazopanib (Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar), two other oral multikinase inhibitors, and temsirolimus (Torisel), an IV multikinase inhibitor, were approved earlier for the same indication.
Med Lett Drugs Ther. 2010 May 3;52(1337):33-4 |  Show IntroductionHide Introduction

Suvorexant (Belsomra) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
hallucinations, sleep paralysis, and other symptoms. Suvorexant promotes sleep by blocking orexin neuropeptides ...
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Smoking Cessation (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
of depression, but has some nicotinicreceptor- blocking activity and may also aid smoking cessation ...
View the Expanded Table: Some Drugs for Smoking Cessation
Med Lett Drugs Ther. 2019 Jul 15;61(1576):e112-4 |  Show IntroductionHide Introduction